ArticleBMC gastroenterology2025
Portal vein thrombosis and associated factors among patients admitted to Tibebe Ghion hospital, Bahir Dar, Ethiopia: a cross-sectional study, 2021-2024.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPortal vein thrombosis (PVT) is a Liver vascular disease characterized by the development of a blood clot inside the portal vein's main branches or trunk. There are limited studies on PVT and associated factors in Africa, with no studies from Ethiopia. Therefore, this study was conducted to assess the prevalence of portal vein thrombosis and associated factors among patients at the TGSH medical ward in Bahir Dar, Ethiopia, from January 1, 2021, to December 31, 2024.
methodA retrospective cross-sectional study was conducted involving 422 patient charts selected through simple random sampling. Data were collected using structured tools, entered into EpiData v4.6, and analyzed using SPSS v25. Bivariate and multivariable logistic regression analyses were performed to identify factors associated with PVT, with statistical significance set at p < 0.05. Ethical clearance was obtained from the Institutional Review Board of Bahir Dar University.
resultA total of 407 study subjects were included, and 64 (15.7%) had portal vein thrombosis. Having a diagnosis of chronic liver disease(CLD), the AOR is 2.139 (95% CI: 1.017-4.499) with a p-value of 0.045, patients with hepatocellular carcinoma (HCC) with an AOR of 3.912 (95% CI: 1.609-9.512) and a significant p-value of 0 003, Platelet count > 450 K, with an AOR of 4.574 (95% CI: 1.989-10.519) and a p-value of 0.001, were significantly associated with portal vein thrombosis. CONCLUSION AND RECOMMENDATIONS: This study found a notably high prevalence of portal vein thrombosis (15.7%) among hospitalized patients, while chronic liver disease, hepatocellular carcinoma, and elevated platelets significantly increasing risk. These findings underscore the need for heightened clinical vigilance and targeted screening in high-risk populations. Future research should focus on elucidating underlying causal mechanisms, including potential thrombophilic conditions, and should incorporate more diverse and representative patient cohorts to inform comprehensive preventive and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.